Navigation Links
Clue to unusual drug-resistant breast cancers found
Date:10/8/2010

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

The study is published in the Oct. 8 issue of the Journal of Biological Chemistry, where it is designated a paper of the week.

Approximately 70 percent of breast cancers express the estrogen receptor. These "ER-positive" tumors usually respond to hormone-related therapies, such as tamoxifen or aromatase inhibitors. But not always.

"We were interested in a subset of ER-positive tumors that are unusually aggressive and also drug-resistant," said Jonna Frasor, assistant professor of physiology and biophysics at the UIC College of Medicine and principal investigator of the study.

Following up on earlier observations that these aggressive ER-positive tumors express genes that respond both to estrogen and inflammatory factors called cytokines, Frasor and her colleagues focused on the gene for a drug-transporter protein which is believed to pump chemotherapy drugs out of tumor cells, making them resistant.

It is unexpected to find estrogen and inflammatory proteins seemingly working together to drive the cancer's aggressiveness, says Madhumita Pradhan, a student in Frasor's lab and first author of the paper. In many cases, estrogen is known to be protective against inflammatory processes, Pradhan said.

The researchers showed that in breast cancer cells, an inflammatory protein called NFĸB and the estrogen receptor act together to increase expression of the transporter gene. And they were able to show how.

An area on a gene called a promoter acts as an on/off switch that determines whether the gene is transcribed and the protein it encodes is produced. The promoter has spaces called response elements, where molecules can attach and help to turn the switch on or off.

"We found that the estrogen receptor gets recruited to the promoter of this gene," Frasor said. "Once there, the ER allows NFĸB to be recruited to its own response element. Once the second molecule binds, it actually stabilizes the ER and the gene is turned on to a much greater extent than with the ER alone."

This novel mechanism could have important implications in the treatment of breast cancers in which inflammation and estrogen can promote cancer progression, Frasor said.


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related biology news :

1. Expedition to Mid-Cayman Rise identifies unusual variety of deep sea vents
2. Unusual rhino beetle behavior discovered
3. Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis
4. Unusual protein modification involved in muscular dystrophy, cancer
5. Unusual microbial ropes grow slowly in cave lake
6. Properties of unusual virus revealed in research
7. Researchers study virus with unusual properties
8. Unusual use of toys in infancy a clue to later autism
9. New methods, new math speed detection of drug-resistant malaria
10. Depressed mice could aid research on drug-resistant depression in humans
11. Drug-resistant urinary tract infections spreading worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
Breaking Biology News(10 mins):
(Date:9/25/2017)...  Renova™ Therapeutics, a biotechnology company developing gene and ... the company,s CEO and Co-founder, Jack W. Reich ... Cell & Gene Therapy CEO forum in ... of Preclinical Research and Pharmacology, Peter Gengo , ... in Boulder, Colorado . Both ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... studies, presentations and demonstrations at SCDM 2017, held September 24-27, 2017 in ... teams and CRO partners for more automated capabilities across evolving data, Comprehend ...
(Date:9/22/2017)... ... September 22, 2017 , ... Precision Periodontics and ... LANAP® and LAPIP™ laser treatments. Drs. Hoge and Zalewsky are members of an ... invasive and less painful option that produces real results. , "Like many of ...
(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar Medical announced today ... manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. ... manufacturing and business services to its Residents. , Vixiar Medical recently closed ...
Breaking Biology Technology: